Mirdametinib
AssetAlso called pd0325901, PD-0325901, PD-901, PD-03525901
Inhibits MEK1 and MEK2, reducing MAPK signaling and tumor growth.
- Stage
- Approved
- Modality
- Small molecule
- Target
- MAP2K2
- 4
- Indications
- 10
- Trials
- 2
- Developers
Indications
5No named disease
Approved, open.fda.gov, Feb 11, 2025
Neurofibromatosis type 1
Phase 2, Active not recruiting, NCT03962543, clinicaltrials.gov, Oct 23, 2026
Plexiform neurofibroma
Phase 2, Active not recruiting, NCT03962543, clinicaltrials.gov, Oct 23, 2026
2 more
In the full profile
- Target and mechanism3
- Owner and partners2
- Trials10
- Evidence for its targets4
- Competitors12
- Signals6
Every asset’s record: target, stage, trials and the evidence behind it.